HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.

Abstract
Hypoxia and dysfunctional tumor vessels represent a prominent feature of pancreatic cancer, being, at least in part, responsible for chemotherapy resistance and immune suppression in these tumors. We tested whether the increase of oxygen delivery induced in vivo by myo-inositol trispyrophosphate (ITPP) can reverse hypoxia, control tumor growth and improve chemotherapy response. Tumor size, metastatic development (microcomputed tomography scan follow-up) and the survival of rats and nude or NOD.SCID mice, (bearing syngenic rat and MiaPaCa2- or patient-derived pancreatic tumors), were determined on ITPP and/or gemcitabine treatment. Partial oxygen pressure, expression of angiogenic factors and tumor histology were evaluated. Infiltration and oxidative status of immune cells, as well as chemotherapy penetration in tumors, were determined by fluorescence-activated cell sorting, fluorometry, nitric oxide release assays, Western blot and confocal microscopy. Weekly intravenous ITPP application resulted in the inhibition of metastasis development and restricted primary tumor growth, showing a superior effect on the rats' survival compared with gemcitabine. ITPP treatment restored tumor normoxia and caused a reduction in hypoxia inducible factor-1α levels, with subsequent VEGF and Lox downregulation, resulting in improved vessel structure and decreased desmoplasia. The latter effects translated into elevated immune cells influx and improved susceptibility to gemcitabine treatment. Growth of human pancreatic tumor xenografts was strongly inhibited by administration of ITPP. ITPP exploits a two-stage mechanism causing rapid, early and sustainable late stage normoxia. This is due to the angiogenic factor modulation and vascular normalization, leading to enhanced chemotherapy delivery and synergistic life prolongation, on combination with low doses of gemcitabine.
AuthorsZahary Raykov, Svitlana P Grekova, Gaétan Bour, Jean Marie Lehn, N A Giese, Claude Nicolau, Marc Aprahamian
JournalInternational journal of cancer (Int J Cancer) Vol. 134 Issue 11 Pg. 2572-82 (Jun 01 2014) ISSN: 1097-0215 [Electronic] United States
PMID24214898 (Publication Type: Journal Article)
Copyright© 2013 UICC.
Chemical References
  • Antimetabolites, Antineoplastic
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Inositol Phosphates
  • RNA, Messenger
  • inositol trispyrophosphate
  • Deoxycytidine
  • Oxygen
  • Gemcitabine
Topics
  • Animals
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Apoptosis (drug effects)
  • Blotting, Western
  • Cell Proliferation (drug effects)
  • Deoxycytidine (analogs & derivatives, therapeutic use)
  • Drug Synergism
  • Fluorescent Antibody Technique
  • Humans
  • Hypoxia (drug therapy, metabolism, pathology)
  • Hypoxia-Inducible Factor 1, alpha Subunit (antagonists & inhibitors, metabolism)
  • Inositol Phosphates (therapeutic use)
  • Liver Neoplasms (drug therapy, metabolism, secondary)
  • Male
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Neovascularization, Pathologic
  • Oxygen (metabolism)
  • Pancreatic Neoplasms (drug therapy, metabolism, pathology)
  • RNA, Messenger (genetics)
  • Rats
  • Rats, Inbred Lew
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tumor Cells, Cultured
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: